Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

By D. Gandara, S. M. Paul, M. Kowanetz, E. Schleifman, W. Zou, Yan Li, A. Rittmeyer, L. Fehrenbacher, G. Otto, C. Malboeuf and 12 more. Nature Medicine, 2018

1,039 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/18375168e3851cfbc077ffed27ffc665edca8328

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann
3. Razelle Kurzrock

Citations in the corpus

• Liquid Biopsy: From Discovery to Clinical Application. (2021, neutral): “Melanoma (besides NSCLC) is also the tumor type with the most impressive responses to ICI—a therapeutic concept that has revolutionized cancer therapy.”
• Molecular profiling for precision cancer therapies (2020, background): “TMB can be assessed either on tumor samples or using ctDNA from blood samples [130, 131].”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Unique assays and cut-offs are not yet defined but preliminary data from the POPLAR and OAK trials found TMB in blood is associated with improved atezolizumab clinical benefit in patients with NSCLC [69].”
• Liquid biopsy: current technology and clinical applications (2022, background): “Blood-based TMB could identify patients who would derive benefit from the antiPDL1 antibody atezolizumab in second line therapy and beyond [39].”